Silence Therapeutics - Patients - C3 Glomerulopathy

You may find the following resources helpful for further reading on the topic of C3G.

The Renal Association: MPGN, DDD & C3 Glomerulopathy | The Renal Association
The National Kidney Foundation: C3G (complement 3 glomerulopathy) | National Kidney Foundation
MPGN/DDD: MPGN/DDD Support Group
Kidneeds: Patients and Families | Kidneeds (uiowa.edu)
Health Unlocked: About - C3 Glomerulopathy | HealthUnlocked
National Organization for Rare Disorders: C3 Glomerulopathy: Dense Deposit Disease and C3 Glomerulonephritis - NORD (National Organization for Rare Disorders) (rarediseases.org)
The National Renal Complement Therapeutics Centre has information on C3G for both patients and clinicians: Management of C3G | National Renal Complement Theraputics Centre (atypicalhus.co.uk)

All clinical trials: www.ClinicalTrials.gov
Caravaca-Fontán F, Lucientes L, Cavero T, et al. Update on C3 Glomerulopathy: A Complement-Mediated Disease. Nephron. 2020;144(6):272-280. doi: 10.1159/000507254. Available at: https://pubmed.ncbi.nlm.nih.gov/32369815/.
Pickering M, D'Agati V, Nester C, et al. C3 glomerulopathy: consensus report. Kidney Int. 2013 Dec;84(6):1079-89. doi: 10.1038/ki.2013.377. Available at: https://pubmed.ncbi.nlm.nih.gov/24172683/.
Smith R, Appel G, Blom A, et al. C3 glomerulopathy - understanding a rare complement-driven renal disease. Nat Rev Nephrol. 2019 Mar;15(3):129-143. doi: 10.1038/s41581-018-0107-2. Available at: https://pubmed.ncbi.nlm.nih.gov/30692664/.

Further reading